Drug class
Phosphatidylinositol-3-kinase alpha (PI3Kα) inhibitor; targeted antineoplastic
Mechanism of action
Inhibits phosphatidylinositol-3-kinase with predominant activity against the alpha isoform (PI3Kα), including mutant p110α encoded by PIK3CA, reducing downstream AKT signalling and tumour-cell growth.
General use cases
- In combination with fulvestrant for adults with HR-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer after progression on or after an endocrine-based regimen
- Treatment of severe manifestations of PIK3CA-related overgrowth spectrum (PROS) requiring systemic therapy in adults and paediatric patients aged 2 years and older under the US FDA Vijoice indication; the oncology and PROS formulations/labels are distinct
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
